TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01

CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ -- Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company, today announced the completion of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy aimed at the treatment of clot-induced...